This scenario explores how next-generation anticoagulant drugs may be at risk of not being developed due to the Inflation Reduction Act (IRA) limitations on R&D incentives through Medicare price setting. These drugs are estimated to prevent 18,000 strokes and avoid 34,000 major bleeding events annually. The IRA could halt the progress of these critical treatments, negatively impacting patients who rely on anticoagulants to manage their conditions and avoid severe health complications.
The analysis was commissioned by the Partnership to Fight Chronic Disease (PFCD) and conducted by Lumanity.
